{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"All toxicities with a maximum grade and status of ≥ grade 2 will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.","groups":[{"description":"The proposed study is designed as a Phase II, multi-center trial of lenalidomide intensification in patients with asymptomatic POD while on low dose lenalidomide maintenance after HDM/ASCT or on continuous/maintenance therapy after initial treatment.","id":"OG000","title":"Lenalidomide"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"every 28 days before initiation of a new cycle through study completion until disease progression up to 5 years","title":"Number of Participants Evaluated for Toxicity","type":"SECONDARY","unitOfMeasure":"Participants"}